ESR1 and breast carcinoma: Adjuvant endocrine therapies such as tamoxifen, a selective estrogen receptor modulator, and aromatase inhibitors (AIs) such as anastrozole, letrozole, or exemestane are often administered as maintenance therapy to individuals with breast cancer who have completed curative treatment [3].